The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Neuroblastoma is an embryonal malignancy that commonly affects young children and is remarkably heterogenous in its malignant potential. Recently, the genetic basis of neuroblastoma has come into focus and not only has catalyzed a more comprehensive understanding of neuroblastoma tumorigenesis but also has revealed novel oncogenic vulnerabilities that are being therapeutically leveraged. Neuroblastoma...
BackgroundA phase I study was conducted to determine the maximum‐tolerated dose, dose‐limiting toxicities (DLTs), and pharmacokinetics of fenretinide (4‐HPR) delivered in an oral powderized lipid complex (LXS) in patients with relapsed/refractory neuroblastoma.
Procedure4‐HPR/LXS powder (352–2,210 mg/m2/day) was administered on Days 0–6, in 21‐day courses, by standard 3 + 3 design.
ResultsThirty‐two...
BackgroundABT‐751, an orally bioavailable sulfonamide, binds β‐tubulin to inhibit microtubule polymerization. We described response and event‐free survival (EFS) in children with neuroblastoma and other solid tumors receiving ABT‐751, assessed in vitro cytotoxicity of ABT‐751 and evaluated the effect of ABT‐751 on tubulin polymerization in peripheral blood mononuclear cells (PBMC) and pediatric tumor...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.